Table 1 Patient characteristics (N = 110)
Characteristic | Category | N (%)/median [range] | P | ||
|---|---|---|---|---|---|
Overall (n = 110) | Before amendment* (n = 67) | After amendment* (n = 43) | |||
Age (years) | 37 (17–87) | 34 (17–87) | 42 (18–79) | 0.02 | |
Gender | Male | 52 (47) | 31 (46) | 21 (49) | 0.80 |
ECOG performance status | ≥ 2 | 19 (17) | 11 (16) | 8 (19) | 0.76 |
WBC (× 109/L) | Median | 3.4 (0.1–194.7) | 3.7 (0.1–194.7) | 3.1 (0.8–129.9) | 0.78 |
≥ 50 | 4 (4) | 2 (3) | 2 (5) | 0.65 | |
PB blasts percentage | 2.5 (0–97) | 3 (0–93) | 2 (0–97) | 0.94 | |
BM blasts percentage | 70 (6–98) | 72 (8–98) | 50 (6–96) | 0.28 | |
BM blasts ≥ 50% | 69 (63) | 47 (70) | 22 (51) | 0.04 | |
Karyotype | Diploid | 28 (25) | 14 (21) | 14 (33) | 0.17 |
Other | 26 (24) | 17 (25) | 9 (21) | 0.60 | |
Complex | 13 (12) | 10 (15) | 3 (7) | 0.21 | |
KMT2A rearrangement | 10 (9) | 8 (12) | 2 (5) | 0.19 | |
Ho-tr | 12 (11) | 4 (6) | 8 (19) | 0.04 | |
HeH | 3 (3) | 3 (4) | 0 | 0.16 | |
Tt | 2 (2) | 1 (1) | 1 (2) | 0.75 | |
IM/ND | 16 (15) | 10 (15) | 6 (14) | 0.89 | |
High-risk cytogenetics** | 22 (20) | 12 (18) | 10 (23) | ||
Ph-like (RNA sequencing) | 20 (18) | 7 (10) | 13 (30) | ||
CRLF2 overexpression*** | 12/71 (17) | 6/34 (18) | 6/37 (16) | 0.87 | |
TP53 mutation | 19/60 (32) | 9/24 (38) | 10/36 (28) | 0.61 | |
CD22 expression | Median | 95.4 (14.3–100) | 95.6 (20–100) | 95.2 (14.3–99.9) | 0.90 |
CD19 expression | Median | 99.9 (0.5–100) | 99.9 (0.5–100) | 99.9 (10.5–100) | 0.74 |
CD20 expression | ≥ 20% | 28 (25) | 12 (18) | 16 (37) | 0.02 |
Prior ASCT | 21 (19) | 19 (28) | 2 (5) | 0.002 | |
Salvage status | Salvage 1 | 79 (72) | 38 (57) | 41 (95) | < 0.001 |
Salvage 1, primary refractory | 15 (14) | 5 (7) | 10 (23) | ||
Salvage 1, CRD1 < 12 months | 26 (24) | 17 (25) | 9 (21) | ||
Salvage 1, CRD1 ≥ 12 months | 38 (35) | 16 (24) | 22 (51) | ||
Salvage 2 | 17 (15) | 15 (22) | 2 (5) | ||
≥ Salvage 3 | 14 (13) | 14 (21) | 0 | ||